1422057-38-2 Usage
Description
(6-fluoro-1H-indol-4-yl)MethanaMine, also known as 6-fluoro-1H-indole-4-methanamine, is a chemical compound with the molecular formula C9H9FN2. It is a derivative of indole, an aromatic heterocyclic organic compound. (6-fluoro-1H-indol-4-yl)MethanaMine is a potential serotonin 5-HT3 receptor antagonist, which means it has the ability to block the action of the neurotransmitter serotonin at this specific receptor site. Its potential applications in pharmacology and medicinal chemistry are currently under scientific research and exploration, focusing on the development of compounds that can modulate serotonin activity in the body.
Uses
Used in Pharmaceutical Industry:
(6-fluoro-1H-indol-4-yl)MethanaMine is used as a pharmaceutical compound for its potential role as a serotonin 5-HT3 receptor antagonist. Its application is based on the ability to block the action of serotonin at the 5-HT3 receptor site, which may lead to the development of new treatments for conditions related to serotonin dysregulation.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (6-fluoro-1H-indol-4-yl)MethanaMine is used as a research compound to explore its potential in modulating serotonin activity. This research may contribute to the development of novel therapeutic agents for various disorders associated with serotonin imbalances.
Check Digit Verification of cas no
The CAS Registry Mumber 1422057-38-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,2,0,5 and 7 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1422057-38:
(9*1)+(8*4)+(7*2)+(6*2)+(5*0)+(4*5)+(3*7)+(2*3)+(1*8)=122
122 % 10 = 2
So 1422057-38-2 is a valid CAS Registry Number.
1422057-38-2Relevant articles and documents
SERINE/THREONINE PAK1 INHIBITORS
-
Page/Page column 159, (2013/03/26)
Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.